Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avanir grant

This article was originally published in The Tan Sheet

Executive Summary

NIH awards Avanir Pharmaceuticals a $100,000 Phase I Small Business Innovation Research grant to test docosonal with known antiviral agents, including acyclovir and other nucleoside antivirals. NIH issued the grant based on Avanir data indicating n-docosanol enhances the antiviral activity of nucleoside analogs against replication of several herpes viruses in vitro. Avanir says the funds will enable the firm to further study combination treatments to "provide more effective control of serious cases of herpes infections." Avanir's Abreva (docosonal 10%) cream is the first FDA-approved OTC for the treatment of cold sores and fever blisters (1"The Tan Sheet" July 31, p. 3). The firm had previously received one "not approvable" letter from FDA for the product, not two as reported in "The Tan Sheet"
Advertisement

Related Content

Avanir Abreva Cold Sore/Fever Blister Cream Approved By FDA
Avanir Abreva Cold Sore/Fever Blister Cream Approved By FDA

Topics

Advertisement
UsernamePublicRestriction

Register

PS091499

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel